Upregulation and sustained coexpression of coinhibitory receptors is regarded as the hallmark of CTL exhaustion; immune checkpoint blockade targeting CTLA-4 and/or PD-1/PD-L1 has achieved considerable success in the treatment of melanoma and other cancers (39–42). The gene discussed is PDCD1; the disease is melanoma.